Pathogenesis and therapy of gastric and duodenal ulcer disease

Medical Clinics of North America

Volumn 86, Issue 6, 2002, Pages 1447-1466

  Shiotani, Akiko ^a   Graham, David Y ^b,c  

^a WAKAYAMA UNIVERSITY   (Japan)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; BISMUTH; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; CARDIOVASCULAR DISEASE; DUODENUM ULCER; DYSGEUSIA; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERTENSION; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; STOMACH ULCER; TACHYCARDIA; VAGINITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH ULCER;

EID: 0036867979     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00083-4     Document Type: Review

References (111)

1. Kurata JH. Ulcer epidemiology: An overview and proposed research framework. Gastroenterology 1989;96:569-80.
2. Kurata JH, Nogawa AN, Abbey DE, et al. A prospective study of risk for peptic ulcer disease in Seventh-Day Adventists. Gastroenterology 1992;102:902-9.
3. Watanabe Y, Kurata JH, Kawamoto K, et al. Epidemiological study of peptic ulcer disease among Japanese and Koreans in Japan. J Clin Gastroenterol 1992;15:68-74.
4. Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal anti-inflammatory drug use and Helicobacter-pylori infection. Gastroenterology 1991;100:1653-7.
5. Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori. Gastroenterology 1992; 102:1899-905.
6. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000;321:1183-7.
7. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-15.
8. Steer HW, Colin-Jones DG. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. Gut 1975;16:590-7.
9. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999;14:176-80.
10. Graham DY, Yamaoka Y. H. pylori and cagA: Relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998;3:145-51.
11. Censini S, Lange C, Xiang Z, et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996;93:14648-53.
12. Yamaoka Y, Kwon DH, Graham DY. A M (r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 2000;97:7533-8.
13. Scott DR, Weeks D, Hong C, et al. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 1998;114:58-70.
14. Icatlo FC, Goshima H, Kimura N, et al. Acid-dependent adherence of Helicobacterpylori urease to diverse polysaccharides. Gastroenterology 2000;119:358-67.
15. Kihl B, Olbe L. Inhibition of pentagastrin-stimulated gastric acid secretion by graded intraduodenal administration of oleic acid in man. Scand J Gastroenterol 1981;16:121-8.
16. Sjovall M, Lindstedt G, Olbe L, et al. Defective inhibition of gastrin release by antral distension in duodenal ulcer patients. Digestion 1992;51:1-9.
17. Walsh JH, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 1975;55:462-8.
18. Blair III AJ, Feldman M, Barnett C, et al. Detailed comparison of basal and food-stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects. J Clin Invest 1987;79:582-7.
19. Dore MP, Graham DY. Pathogenesis of duodenal ulcer disease: The rest of the story. Baillieres Clin Gastroenterol 2000;14:97-107.
20. Graham DY, Dore MP. Perturbations in gastric physiology in Helicobacter pylori duodenal ulcer: Are they all epiphenomena? Helicobacter 1997;1(Suppl 2):S44-9.
21. Bode G, Malfertheiner P, Mader U, et al. Fine structure of active and healed duodenal ulcer. Am J Gastroenterol 1991;86:179-86.
22. El-Zimaity HM, Wu J, Akamatsu T, Graham DY. A reliable method for the simultaneous identification of H. pylori and gastric metaplasia in the duodenum. J Clin Pathol 1999; 52:914-6.
23. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96:615-25.
24. Noach LA, Rolf TM, Bosma NB, et al. Gastric metaplasia and Helicobacter pylori infection. Gut 1993;34:1510-4.
25. Wyatt JI, Rathbone BJ, Sobala GM, et al. Gastric epithelium in the duodenum: Its association with Helicobacter pylori and inflammation. J Clin Pathol 1990;43:981-6.
26. Graham DY, Osato MS. H. pylori in the pathogenesis of duodenal ulcer: Interaction between duodenal acid load, bile, and H. pylori. Am J Gastroenterol 2000;95: 87-91.
27. Isenberg JI, Selling JA, Hogan DL, et al. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med 1987;316: 374-9.
28. Han SW, Evans DG, Zaatari FA, et al. The interaction of pH, bile, and Helicobacter pylori may explain duodenal ulcer. Am J Gastroenterol 1996;91:1135-7.
29. Oi M, Ito Y, Kumagai F, et al. A possible dual control mechanism in the origin of peptic ulcer: A study on ulcer location as affected by mucosa and musculature. Gastroenterology 1969;57:280-93.
30. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med 1988; 319:1707-15.
31. Konturek PC, Brzozowski T, Sliwowski Z, et al. Involvement of nitric oxide and prostaglandins in gastroprotection induced by bacterial lipopolysaccharide. Scand J Gastroenterol 1998;33:691-700.
32. Wallace JL, Keenan CM, Cucala M, et al. Mechanisms underlying the protective effects of interleukin I in experimental nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 1992;102(4 pt 1):1176-85.
33. Byrd JC, Yunker CK, Xu QS, et al. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 2000;18:1072-9.
34. Morgenstern S, Koren R, Moss SF, et al. Does Helicobacter pylori affect gastric mucin expression? Relationship between gastric antral mucin expression and H. pylori colonization. Eur J Gastroenterol Hepatol 2001;13:19-23.
35. Ota H, Nakayama J, Shimizu T, et al. Relation of H. pylori to gastric mucins and gastric surface mucous gel layer. Gut 2001;48:869-71.
36. Graham DY, Yamaoka Y. Disease-specific Helicobacter pylori virulence factors: The unfulfilled promise. Helicobacter 2000;4(suppl 1):S3-9.
37. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model. Gastroenterology 1997;113:1983-91.
38. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;23:404:398-402.
39. Malaty HM, Graham DY, Isaksson I, et al. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? Arch Intern Med 2000:160:105-9.
40. Breuer T, Malaty HM, Graham DY. The epidemiology of H. pylori-associated gastroduodenal diseases. In: Ernst P, Michetti P, Smith PD, editors. The Immunobiology of H. Pylori from Pathogenesis to Prevention. Philadelphia: Lippincott-Raven; 1997. p. 1-14.
41. Mitchell HM, Lee A, Carrick J. Increased incidence of Campylobacter pylori infection in gastroenterologists: Further evidence to support person-to-person transmission of C pylori. Scand J Gastroenterol 1989;24:396-400.
42. Thomas JE, Gibson GR, Darboe MK, et al. Isolation of Helicobacter pylori from human faeces. Lancet 1992;340:1194-5.
43. Leung WK, Siu KL, Kwok CK, et al. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol 1999; 94:2881-4.
44. Megraud F. Transmission of Helicobacter pylori: Faecal-oral versus oral-oral route. Aliment Pharmacol Ther 1995;9(suppl 2):85-91.
45. Parsonnet J, Shmuely, H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999;282:2240-5.
46. Shames B, Krajden S, Fuksa M, et al. Evidence for the occurrence of the same strain of Campylobacter pylori in the stomach and dental plaque. J Clin Microbiol 1989;27: 2849-50.
47. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: Where we stand. Am J Gastroenterol 1996;91:2080-6.
48. Laine L, Sloane R, Ferretti M, et al. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-33.
49. Whittle BJR. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile salts, and the actions of prostaglandins. Br J Pharmacol 1977;60:455-60.
50. Avunduk C, Suliman M, Gang D, et al. Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate. Dig Dis Sci 1991;36:431-4.
51. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999;116:1319-29.
52. Hudson N, Balsitis M, Filipowicz F, et al. Effect of Helicobacter pylori colonization on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 34:748-51.
53. Chan FKL, Sung JJY, Chung SCS, et al. Randomized trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
54. Shiotani A, Graham DY. Interaction between Helicobacter pylori infection and NSAID use. In: Asalura H, Aoyagi Y, Nakazawa S, editors. Trends in Gastroenterology and Hepatology Millennium 2001. Tokyo: Springer; 2001. p. 237-41.
55. Bazzoli F, De Luca L, Graham DY. Helicobacterpylori and the use of NSAIDs. Baillieres Clin Gastroenterol 2001;15:775-85.
56. Feldman M, Cryer B, Mallat D, et al. Role of Helicobacter tylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: A prospective placebo-controlled, double-blind, randomized trial. Am J Gastroenterol 2001;96:1751-7.
57. Laine L, Bombardier C, Hawkey C, et al. Influence of H. pylori and other potential risk factors on clinical gastrointestinal events in a double-blind outcome study of rofecoxib vs. naproxen. Gastroenterology 2000;118:A4798.
58. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Gastroenterology 2000; 118:A1461.
59. Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
60. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of nonsteroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991; 32:252-5.
61. Greenhalgh T. Papers that report drug trials. In: How to Read A Paper. 2nd Edition. London: BMJ Publications; 2001. p. 94-104.
62. Sung JJ, Lau JY, Chan FK, et al. How often are endoscopic ulcers in NSAID trials diagnosed as actual ulcers by experienced endoscopists? Gastroenterology 2001; 120:A597.
63. Graham DY. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: Interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications-future research needs. Am J Med 2001;110(suppl 1):S58-S61.
64. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugsOmeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
65. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non steroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26.
66. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in chronic NSAID users: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 2002;47:1665-78.
67. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330: 377-81.
68. Goldin GF, Peura DA. Stress-related mucosal damage. What to do or not to do. Gastrointest Endosc Clin N Am 1996;6:505-26.
69. Lucas CE, Sugawa C, Riddle J, et al. Natural history and surgical dilemma of "stress" gastric bleeding Arch Surg 1971;102:266-73.
70. Fiddian-Green RG, McGough E, Pittenger G, et al. Predictive value of intramural pH and other risk factors for massive bleeding from stress ulceration. Gastroenterology 1983;85:613-20.
71. Katschinski BD, Logan RF, Edmond M, et al. Physical activity at work and duodenal ulcer risk. Gut 1991;32:983-6.
72. Levenstein S. Stress and peptic ulcer: Life beyond Helicobacter. BMJ 1998;316:538-41.
73. Oektedalen O, Guldvog I, Opstad PK, et al. The effect of physical stress on gastric secretion and pancreatic polypeptide levels in man. Scand J Gastroenterol 1984;19: 770-8.
74. Gibinski K. Step by step towards the natural history of peptic ulcer disease. J Clin Gastroenterol 1983;5:299-302.
75. Graham DY, Akdamar K, Dyck WP, et al. Healing of benign gastric ulcer: Comparison of cimetidine and placebo in the United States. Ann Intern Med 1985;102:573-6.
76. 2-receptor antagonists. Scand J Gastroenterol 1994;29:1140-4.
77. Yamao K, Nakazawa S, Yoshino J, et al. Evaluating gastric ulcer healing by endoscopic ultrasonography. Endoscopy 1994;26:798-9.
78. Graham DY, Qureshi WA. Markers of infection. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacterpylori: Physiology and Genetics. Washington: ASM Press; 2001. p. 499-510.
79. Graham DY, Klein PD, Evans DJ Jr, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet 1987;23:1174-7.
80. Graham DY, Klein PD. Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. Gastroenterol Clin North Am 2000;29:885-93.
81. Graham DY, Reddy S. Rapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography. Aliment Pharmacol Ther 2001;15:699-702.
82. Kato M, Asaka M, Saito M, et al. Clinical usefulness of urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori: A collaborative study in nine medical institutions in Japan. Helicobacter 2000;5:109-19.
83. Yamamoto S, Uemura N, Okamoto S, et al. A new rapid test for detecting anti-Helicobacter pylori antibody excreted into urine. Helicobacter 2000;5:160-4.
84. Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay, HpSA European study group. Lancet 1999; 354:30-3.
85. El-Zimaity HM, Segura AM, Genta RM, et al. Histologic assessment of Helicobacter pylori status after therapy: Comparison of Giemsa, Diff-Quik, and Genta stains. Mod Pathol 1998;11:288-91.
86. El-Zimaity HM, Ota H, Scott S, et al. A new triple stain for Helicobacter pylori suitable for the autostainer: Carbol fuchsin/Alcian blue/hematoxylin-eosin. Arch Pathol Lab Med 1998;122:732-6.
87. Marshall BJ, Warren JR, Francis GJ, et al. Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am J Gastroenterol 1987;82:200-10.
88. Lee JM, Breslin NP, Fallon C, et al. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 2000;95:1166-70.
89. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999;94:725-9.
90. Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: A meta-analytical approach. Dig Dis Sci 2000;45:68-76.
91. Gibson JR, Saunders NA, Burke B, et al. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 1999;37:3746-8.
92. Trebesius K, Panthel K, Strobel S, et al. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridization. Gut 2000;46:608-14.
93. Kirk AP, Dooley JS, Hunt RH. Peptic ulceration in patients with chronic liver disease. Dig Dis Sci 1980;25:756-60.
94. Langman MJ, Cooke AR. Gastric and duodenal ulcer and their associated diseases. Lancet 1976;1:680-3.
95. Robinson PJ, Smith AL, Sly PD. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig Dis Sci 1990;35:1299-304.
96. Rotter JI. Peptic ulcer. In: Emery AEH, Rimoin DL, editors. The Principles and Practice of Medical Genetics. New York: Churchill Livingstone; 1983. p. 1-58.
97. Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994;8(suppl 1):47-52.
98. Bolin TD, Davis AE, Duncombe VM, et al. Role of maintenance sucralfate in prevention of duodenal ulcer recurrence. Am J Med 1987;28:91-4.
99. Jorde R, Burhol PG, Hansen T. Ranitidine 150 mg at night in the prevention of gastric ulcer relapse. Gut 1987;28:460-3.
100. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study. Ann Intern Med 1992;116:705-8.
101. Bazzoli F. My approach to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 1999:11(suppl 1):S37-41.
102. Kung NN, Sung JJ, Yuen NW, et al. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: A prospective randomized controlled trial. Am J Gastroenterol 1999;94:721-4.
103. Sung JJ, Chan FK, Wu JC, et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: The RBC-MACH study. Aliment Pharmacol Ther 1999;13:1079-84.
104. Miehlke S, Graham DY. Antimicrobial therapy of peptic ulcer. Int J Antimicrob Agents 1997;8:171-8.
105. Segura AM, Gutierrez O, Otero W, et al. Furazolidone, amoxicillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:529-32.
106. Gilbert DA, Silverstein FE, Tedesco FJ, et al. The national ASGE survey oil upper gastrointestinal bleeding. III. Endoscopy in upper gastrointestinal bleeding. Gastrointest Endosc 1981;27:94-102.
107. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ 1995;311:222-6.
108. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997;336:1054-8.
109. Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998;158:54-8.
110. Khoursheed M, Fuad M, Safar H, et al. Laparoscopic closure of perforated duodenal ulcer. Surg Endosc 2000;14:56-8.
111. Naesgaard JM, Edwin B, Reiertsen O, et al. Laparoscopic and open operation in patients with perforated peptic ulcer. Eur J Surg 1999;165:209-14.